Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Auris Health Inc.

www.aurishealth.com

Latest From Auris Health Inc.

Miraki Innovation Launches $175M Medical Technology Breakthrough Fund

Christopher Velis, co-founder of Auris Health and founder of Miraki Innovation has launched the Medical Technology Breakthrough Fund, a $175m fund to help finance and build the next-generation of medtech companies.

Innovation Companies

SAGES 2019: Spotlighting Competitive Robotic Systems And Procedures

Surgical robotics giant Intuitive Surgical will soon face competition from Medtronic and Verb Surgical. With the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) annual meeting on the way in Baltimore, MD this week, Wells Fargo analyst Larry Biegelsen offers an outlook on competitive robotic systems and the rising popularity by surgeons to use robotics systems in hernia, bariatric, cholecystectomy and colorectal procedures.

Artificial Intelligence Commercial

Johnson & Johnson Diversifies Robotic Efforts With Auris Health Aquisition

Johnson & Johnson will acquire robotic startup Auris Health for $3.4bn in cash, plus milestones payments of up to $2.4bn. Auris developed the FDA-cleared Monarch platform, which is expected to rival Intuitive Surgical's robotic-assisted bronchoscope device, Ion, awaiting FDA clearance.

Deals Surgery

Device/Diagnostics Quarterly Deal-Making Statistics, Q3 2017

Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.

Medical Device In Vitro Diagnostics
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Auris Surgical Robotics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Auris Health Inc.
  • Senior Management
  • Fred Moll, MD, CEO
    David M Styka, CFO
    Dan Bradford, VP, Operations
    David Mintz, VP, R&D
    David Schummers, VP, Bus. Dev.
    Eric Davidson, VP, Sales & Mktg.
  • Contact Info
  • Auris Health Inc.
    Phone: (650) 610-0750
    150 Shoreline Dr.
    Redwood City, CA 94065
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register